University of South Carolina

Biophytis presented its OBA program with BIO101 at the 17th SCWD congress, highlighting its potential to prevent GLP-1RA-induced muscle loss in obesity. Results from the Quinolia study showed reduced fat mass and maintained muscle strength in 20-hydroxyecdysone-treated patients. A phase 2 OBA study targeting obese patients with GLP-1 RAs is planned for 2025.

Trudy Mackay, Clemson University's first National Academy of Medicine member, pioneers genetic research with fruit flies, impacting human health and precision medicine.

Clemson Board of Trustees approved Phase II renovations to Littlejohn Coliseum, estimated at $40 million, with construction starting in December 2024 and completion by September 2026. The committee deferred discussion on admission fees for non-Clemson Athletic events and a student athletics fee to the full board meeting. Clemson seeks approval for a $150 per semester athletic fee for students, currently the only public college in the state without such fees. Phase I renovations were approved in July 2023, funded privately by IPTAY and boosters.

Senex Biotechnology secures European patent for SNX631-6, a CDK8/19 inhibitor for cancer treatment, complementing its US patent. The drug aims to address drug resistance and metastasis in various cancers, with plans for clinical trials in 2026.

Athletic trainer Kenya Moore noticed a player's disorientation after switching ADHD meds, leading to heat stroke. Experts warn that medications for ADHD, anxiety, and depression elevate heat stroke risk in athletes, calling for more research. Heat illness diagnoses and deaths have risen with global temperatures, with stimulants potentially increasing risk by constricting blood vessels and inhibiting sweating. Awareness and precautions are crucial, especially as mental health medication use rises.